We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The influence of clinical pharmacist-directed PDCA and DRG on the hospital's antitumor treatments and safety management.
- Authors
Gong, Ting; Deng, Min; Lei, Haibo; Wu, Shiwei; Long, Liang; Zou, Yang; Liu, Xiang
- Abstract
Background: To assess the impact of the clinical pharmacist-directed PDCA DRG approach on antitumor treatments and safety management within a hospital setting, specifically focusing on medical expenses, the utilization rate of restricted-level antitumor drugs, and the allocation of expenditure on antitumor drugs and adjunctive medications across different cancer types. Methods: The retrospective study involved a comparative analysis between a control group (n = 105) and a PDCA DRG group (n = 102) across various cancer types. On the basis of the medical insurance policy, the control group received treatment according to the latest medical guidelines, while the PDCA DRG group received treatment based on the clinical pharmacist-directed PDCA and DRG approach. Medical expenses, utilization rates of restricted-level antitumor drugs, rational prescription rate, and the allocation of expenditure on antitumor drugs and adjunctive medications were evaluated. Results: The implementation of the clinical pharmacist-directed PDCA DRG approach led to a significant reduction in medical expenses across different cancer types. The implementation of PDCA DRG approach could effectively improve the rational use of antitumor drugs in surgery department, while it had limited impact on promoting the rational prescription in internal medicine department. The utilization rate of restricted-level antitumor drugs did not show significant differences between the control and PDCA DRG groups. However, there was a notable increase in the proportion of expenditure on antitumor drugs in the PDCA DRG group compared to the control group. Additionally, the PDCA DRG group had a significantly lower proportion of expenditure on adjunctive medications for antitumor drugs. Conclusion: The findings suggest that the implementation of the clinical pharmacist directed PDCA DRG approach in antitumor treatments and safety management within a hospital setting can lead to significant reductions in medical expenses and effective improvement of the rational use of antitumor drugs. While no significant changes were observed in the utilization rate of restricted-level antitumor drugs, the allocation of expenditure showed a higher proportion directed towards antitumor drugs and a lower proportion towards adjunctive medications. These results indicate potential improvements of clinical pharmacist involved approach, especially in cost-efficiency and resource allocation, which can guide healthcare institutions in optimizing antitumor treatments.
- Subjects
ANTINEOPLASTIC agents; HEALTH insurance; MEDICAL care costs; HEALTH policy; INSURANCE policies
- Publication
Indian Journal of Cancer, 2024, Vol 61, Issue 3, p654
- ISSN
0019-509X
- Publication type
Academic Journal
- DOI
10.4103/ijc.ijc_266_24